Cipla Ltd vs Jubilant Pharmova Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Cipla Ltd is ₹ 1292 as of 12 May 15:30 . The P/E Ratio of Cipla Ltd changed from 27.3 on March 2021 to 22.1 on March 2025 . This represents a CAGR of -4.14% over 5 yearsThe P/E Ratio of Jubilant Pharmova Ltd changed from 13 on March 2021 to 16.8 on March 2025 . This represents a CAGR of 5.26% over 5 years The Market Cap of Cipla Ltd changed from ₹ 65746 crore on March 2021 to ₹ 116434 crore on March 2025 . This represents a CAGR of 12.11% over 5 yearsThe Market Cap of Jubilant Pharmova Ltd changed from ₹ 10838 crore on March 2021 to ₹ 14220 crore on March 2025 . This represents a CAGR of 5.58% over 5 years The revenue of Cipla Ltd for the Dec '25 is ₹ 7280 crore as compare to the Sep '25 revenue of ₹ 7858 crore. This represent the decline of -7.35% The revenue of Jubilant Pharmova Ltd for the Dec '25 is ₹ 2143 crore as compare to the Sep '25 revenue of ₹ 1976 crore. This represent the growth of 8.44% The ebitda of Cipla Ltd for the Dec '25 is ₹ 1185 crore as compare to the Sep '25 ebitda of ₹ 2163 crore. This represent the decline of -45.21% The ebitda of Jubilant Pharmova Ltd for the Dec '25 is ₹ 270.2 crore as compare to the Sep '25 ebitda of ₹ 345.3 crore. This represent the decline of -21.75% The net profit of Cipla Ltd changed from ₹ 1176 crore to ₹ 674.56 crore over 7 quarters. This represents a CAGR of -27.22% The net profit of Jubilant Pharmova Ltd changed from ₹ 481.8 crore to ₹ 55.8 crore over 7 quarters. This represents a CAGR of -70.83% The Dividend Payout of Cipla Ltd changed from 16.34 % on March 2021 to 25.05 % on March 2025 . This represents a CAGR of 8.92% over 5 yearsThe Dividend Payout of Jubilant Pharmova Ltd changed from 37.14 % on March 2021 to 414.06 % on March 2025 . This represents a CAGR of 61.97% over 5 years .

About Cipla Ltd

Cipla Limited is one of the leading pharmaceutical companies in India.
The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
Cipla's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments.
With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets.
Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Limited was incorporated in year 1935 with the name as 'Chemical, Industrial & Pharmaceutical Laboratories Limited'.

About Jubilant Pharmova Ltd

Jubilant Pharmova Limited was initially incorporated as 'Vam Organic Chemicals Limited' on June 21, 1978.
Company name was changed to 'Jubliant Organosys Limited' in November, 2001 and was again changed to 'Jubilant Life Sciences Limited' in October, 2009 and further it attained a new name 'Jubilant Pharmova Limited' in February, 2021. Jubilant Pharmova Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.
The Company is engaged in pharmaceuticals, contract research and development services and proprietary novel drugs.
The pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of Active Pharmaceutical Ingredients (APIs), Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non-Sterile Products through 6 US FDA approved manufacturing facilities in India, USA and Canada with a network of over 48 radiopharmacies in the USA.

FAQs for the comparison of Cipla Ltd and Jubilant Pharmova Ltd

Which company has a larger market capitalization, Cipla Ltd or Jubilant Pharmova Ltd?

Market cap of Cipla Ltd is 105,391 Cr while Market cap of Jubilant Pharmova Ltd is 15,879 Cr

What are the key factors driving the stock performance of Cipla Ltd and Jubilant Pharmova Ltd?

The stock performance of Cipla Ltd and Jubilant Pharmova Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cipla Ltd and Jubilant Pharmova Ltd?

As of May 12, 2026, the Cipla Ltd stock price is INR ₹1304.7. On the other hand, Jubilant Pharmova Ltd stock price is INR ₹996.85.

How do dividend payouts of Cipla Ltd and Jubilant Pharmova Ltd compare?

To compare the dividend payouts of Cipla Ltd and Jubilant Pharmova Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.